Tumors exploit a nociceptor-SLIT2-CGRP nerve circuit to suppress T-cell function and evade immune surveillance, with disruption restoring immunotherapy efficacy.
Neural immune evasionTumors exploit CGRP-producing pain nerves to suppress T-cell function and evade immunotherapy
What the researchers found
Tumors hijack an interorgan nociceptor-SLIT2-CGRP neural circuit to drive systemic immunosuppression, and disrupting this loop restores T-cell function and enhances immunotherapy efficacy.
Why it matters
Understanding how tumors use the nervous system to escape immunity could lead to entirely new cancer treatments that combine nerve-blocking drugs with immunotherapy.
How the study worked
Research commentary on the discovery of a tumor-exploited nociceptor-SLIT2-CGRP circuit that mediates immune evasion, with experimental disruption restoring anti-tumor immunity.
What this study cannot tell us
Commentary on primary research — specific experimental details in the original study. Translation to human tumors needs validation.
How to read the evidence
Research commentary on preclinical discovery — highlights a paradigm-shifting mechanism that needs clinical validation.
When this study was published
Published in 2026; at the forefront of cancer neuroscience.
The bigger picture
This is part of a revolutionary understanding that the nervous system actively participates in cancer progression — not just as a pain carrier but as an immune suppressor.
Questions still open
- Could existing CGRP-targeting migraine drugs (like erenumab) enhance cancer immunotherapy?
- Which cancer types most rely on this nerve-immune evasion circuit?
Common questions
How do tumors hide from the immune system using nerves?
Could migraine drugs help fight cancer?
Read the original research
Nociceptive neuroimmune circuit drives immune evasion.
Trends in cancer
Citation
Cao, Canhui. (2026). Nociceptive neuroimmune circuit drives immune evasion.. Trends in cancer. https://doi.org/10.1016/j.trecan.2026.01.003